Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2000

Primary Completion Date

December 31, 2001

Study Completion Date

April 30, 2002

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

BMS-214662

This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.

DRUG

paclitaxel

Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.

Trial Locations (2)

44106-5065

Ireland Cancer Center at University Hospitals Case Medical Center, Cleveland

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00006018 - Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter